Skip to main content

Table 3 Cumulative incidence of adverse events (AEs) in the safety population by study week

From: Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease

  Donepezil 23–23 Donepezil 10–23
  N = 570 N = 332
  1 week 2 weeks 4 weeks 52 weeks (total duration) 1 week 2 weeks 4 weeks 52 weeks (total duration)
Patients with at least 1 AE, % 15.8 18.6 23.2 72.8 20.8 25.9 31.9 78.0
Patients who discontinued due to AEs, % 0.5 1.6 2.3 11.4 2.4 3.9 4.8 17.5
Patients with AEs, %         
 Diarrhea 0.4 0.4 0.9 3.5 1.5 2.1 2.7 5.7
 Nausea 0.2 0.2 0.2 2.1 3.9 4.2 4.2 6.0
 Vomiting 0.0 0.0 0.0 1.6 2.4 2.4 2.7 4.5
 Dizziness 0.4 0.4 0.5 1.1 0.9 1.2 1.5 3.6